What is the mechanism of action of this treatment?

Ultra-Low-Dose Total Skin Electron Beam Therapy (ULD-TSEBT) works by delivering targeted radiation to the skin, which helps to destroy cancerous cells while minimizing damage to surrounding healthy tissue. Brentuximab Vedotin is an antibody-drug conjugate that targets CD30-positive cells, delivering a cytotoxic agent directly to the cancer cells, leading to their destruction. These treatments are significant for Mycosis Fungoides patients because they offer targeted approaches that can effectively reduce tumor burden and manage symptoms with potentially fewer side effects compared to more generalized treatments. This targeted approach is crucial in managing a disease that primarily affects the skin and can significantly impact the patient's quality of life.

What side effects are associated with this type of intervention?

Ultra-Low-Dose Total Skin Electron Beam Therapy (ULD-TSEBT) commonly causes skin-related side effects such as erythema, dryness, itching, and peeling, with more severe but less common effects including blistering and secondary infections. Brentuximab Vedotin can cause peripheral neuropathy, fatigue, nausea, diarrhea, fever, and neutropenia, with severe side effects potentially including serious infections and infusion-related reactions.

What prior FDA approvals exist?

The FDA has approved several treatments for Mycosis Fungoides, a type of cutaneous T-cell lymphoma. Brentuximab Vedotin, an antibody-drug conjugate targeting CD30-positive cells, is one such treatment. It has shown efficacy in patients with CD30-expressing cutaneous T-cell lymphomas, including Mycosis Fungoides. Additionally, localized radiation therapies, such as Total Skin Electron Beam Therapy (TSEBT), have been used to manage skin lesions in Mycosis Fungoides. These treatments aim to control symptoms and improve quality of life in affected patients.

What other types of research exist?

Promising novel alternatives for Mycosis Fungoides treatment in 2024 include: 1) Mogamulizumab, a monoclonal antibody targeting CCR4, which has shown efficacy in clinical trials for cutaneous T-cell lymphoma. 2) Pembrolizumab, an immune checkpoint inhibitor targeting PD-1, which has demonstrated potential in treating relapsed or refractory Mycosis Fungoides. 3) Localized radiation options such as Total Skin Electron Beam Therapy (TSEBT) at higher doses or fractionated schedules, which may offer improved outcomes for some patients.

← Back to Search

Monoclonal Antibodies

Total-Skin Electron Beam Therapy + Brentuximab for Skin Cancer

Houston, TX

Phase 2

Recruiting

Led By Bouthaina Dabaja, MD

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

18 years of age or older

ECOG performance status score of ≤ 3

Must not have

Severe renal impairment (CrCL <30 mL/min)

Underlying medical conditions including unstable cardiac disease or other serious illness that would impair treatment

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a combination of low-dose skin radiation and a targeted cancer drug. It focuses on patients with a specific type of skin lymphoma that is hard to treat. The treatment works by using radiation to reduce cancer cells on the skin and a drug to kill them directly.

See full description

Who is the study for?

This trial is for adults with relapsed/refractory mycosis fungoides, a type of skin lymphoma. Participants must have at least 1% CD30 expression in their cancer cells and be stable on certain medications if needed. HIV+ patients can join if treated and with a CD4 count >200. People are excluded if they have severe kidney or liver issues, another primary malignancy treatment, grade 2+ neuropathy, or women not using birth control.Check my eligibility

What is being tested?

The study tests ultra-low-dose total-skin electron beam therapy (ULD-TSEBT) combined with brentuximab vedotin to see its effectiveness against mycosis fungoides over a year. There's no wait time after previous cancer treatments before starting this trial.See study design

What are the potential side effects?

Potential side effects include reactions related to the immune system such as infusion reactions from brentuximab vedotin, nerve damage (neuropathy), fatigue, skin irritation from radiation therapy, and increased risk of infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

show original

Select...

I am capable of only limited self-care, confined to a bed or chair more than 50% of waking hours.

show original

Select...

My skin cancer is confirmed as mycosis fungoides at stage I-IV.

show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

My kidney function is severely impaired.

show original

Select...

I do not have any serious illnesses that would affect my treatment.

show original

Select...

I am not using other cancer treatments for mycosis fungoides or Sezary syndrome.

show original

Select...

I have moderate to severe nerve pain or tingling.

show original

Select...

My liver function is moderately or severely impaired.

show original

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2024 Phase 4 trial • 50 Patients • NCT01909934

18%

Pyrexia

18%

Peripheral sensory neuropathy

16%

Diarrhoea

16%

Neutropenia

14%

Anaemia

12%

Fatigue

10%

Nausea

10%

Arthralgia

Cough

Constipation

Vomiting

Neuropathy peripheral

Back pain

Decreased appetite

Upper respiratory tract infection

Oedema peripheral

Malaise

Paraesthesia

Peripheral motor neuropathy

Thrombocytopenia

Myalgia

Pain in extremity

Hyponatraemia

General physical health deterioration

Pneumonia

Hypotension

Anaplastic large-cell lymphoma

Dyspnoea

Upper gastrointestinal haemorrhage

Death

Epididymitis

Malnutrition

Aortic stenosis

Chronic obstructive pulmonary disease

Pneumonitis

Central nervous system haemorrhage

Ischaemic stroke

Autonomic neuropathy

Cardiac failure acute

Abdominal incarcerated hernia

Colitis

Large intestinal haemorrhage

Small intestinal perforation

Haematemesis

Hypokalaemia

Invasive lobular breast carcinoma

Acute respiratory failure

Respiratory failure

Dehydration

100%

80%

60%

40%

20%

Study treatment Arm

Brentuximab Vedotin 1.8 mg/kg

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Brentuximab vedotinExperimental Treatment1 Intervention

Participant will receive radiation therapy to the entire skin surface over the course of 2 days. Each dose will take about 60 to 90 minutes and will vary from one patient to another

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Brentuximab vedotin

2016

Completed Phase 4

~290

0 / 8Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Ultra-Low-Dose Total Skin Electron Beam Therapy (ULD-TSEBT) works by delivering targeted radiation to the skin, which helps to destroy cancerous cells while minimizing damage to surrounding healthy tissue. Brentuximab Vedotin is an antibody-drug conjugate that targets CD30-positive cells, delivering a cytotoxic agent directly to the cancer cells, leading to their destruction. These treatments are significant for Mycosis Fungoides patients because they offer targeted approaches that can effectively reduce tumor burden and manage symptoms with potentially fewer side effects compared to more generalized treatments. This targeted approach is crucial in managing a disease that primarily affects the skin and can significantly impact the patient's quality of life.